{"nctId":"NCT00381303","briefTitle":"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.","startDateStruct":{"date":"2006-11"},"conditions":["HIV","Infectious"],"count":429,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: darunavir","Drug: ritonavir"]}],"interventions":[{"name":"darunavir","otherNames":[]},{"name":"ritonavir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented HIV infection\n* Plasma HIV-RNA \\>= 1000 copies/mL\n* Must be able to comply with protocol requirements\n\nExclusion Criteria:\n\n* No prior use of PREZISTA (darunavir), TMC125, enfuvirtide, or tipranavir\n* No currently active AIDS defining illness, Category C conditions according to the Center for Disease Control \\[CDC\\] Classification System for HIV Infection (1993) with the following exceptions, which must be discussed with the Sponsor prior to enrollment: stable cutaneous Kaposi's Sarcoma, Wasting syndrome due to HIV infection\n* Not currently using an investigational drug\n* Not pregnant or breastfeeding\n* No Grade 3 or 4 laboratory abnormality as defined by DAIDS (Division of AIDS, National Institute of Allergy and Infectious Diseases).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Viral Load (VL) < 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex","description":"TLOVR - responders/non-responders per FDA TLOVR response algorithm. A subject was considered a responder at that time point and that subsequent. A subject was considered a non-responder at a time point in the following situations: discontinued treatment at that time point, a rebound value at that time point and that subsequent or at that time point and that followed by treatment discontinuation, intermittent missing values were considered a response if the immediately preceding and following visits were a response, rebound at earlier time point, or any new, unplanned ARV except in tolerability","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of VL < 50 HIV-1 RNA Copies/mL (TLOVR) Subjects by Race","description":"Intention to Treat population (ITT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Etravirine-TMC125 (ETR) Subgroup- VL < 50 HIV-1 RNA Copies/mL (TLOVR) Subjects","description":"The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":"0.088"},{"groupId":"OG001","value":"54","spread":"0.131"},{"groupId":"OG002","value":"74","spread":"0.092"},{"groupId":"OG003","value":"21","spread":"0.191"},{"groupId":"OG004","value":"25","spread":"0.158"},{"groupId":"OG005","value":"2","spread":"0.472"},{"groupId":"OG006","value":"1","spread":"-1.73"}]}]}]},{"type":"SECONDARY","title":"Descriptive Statistics of [TLOVR Non-virologic Failure (VF) Censored] - VL < 50 HIV-1 RNA by Race","description":"TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Descriptive Statistics of ETR Subgroup [TLOVR Non-virologic Failure (VF) Censored] - VL < 50 HIV-1 RNA","description":"The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)\n\nTLOVR non-virologic failure(VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"21","spread":null},{"groupId":"OG004","value":"25","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using Observed Values","description":"Observed obsevations have no imputation methods applied.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":"11.2"},{"groupId":"OG001","value":"122","spread":"12.3"},{"groupId":"OG002","value":"143","spread":"10.8"},{"groupId":"OG003","value":"151","spread":"23.8"},{"groupId":"OG004","value":"133","spread":"17.0"},{"groupId":"OG005","value":"45","spread":"24.5"},{"groupId":"OG006","value":"179","spread":null}]}]}]},{"type":"SECONDARY","title":"Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Using Observed Values","description":"The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":"15.8"},{"groupId":"OG001","value":"108","spread":"15.1"},{"groupId":"OG002","value":"135","spread":"13.5"},{"groupId":"OG003","value":"111","spread":"26.7"},{"groupId":"OG004","value":"98","spread":"29.8"},{"groupId":"OG005","value":"45","spread":"24.5"},{"groupId":"OG006","value":"179","spread":null}]}]}]},{"type":"SECONDARY","title":"Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using the Imputation Method of Last Observation Carried Forward (LOCF)","description":"Last Observation Carried Forward (LOCF) imputation method applied.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":"8.8"},{"groupId":"OG001","value":"103","spread":"11.2"},{"groupId":"OG002","value":"109","spread":"8.9"},{"groupId":"OG003","value":"110","spread":"20.4"},{"groupId":"OG004","value":"109","spread":"13.5"},{"groupId":"OG005","value":"45","spread":"24.5"},{"groupId":"OG006","value":"138","spread":"41.0"}]}]}]},{"type":"PRIMARY","title":"Number of TLOVR Non-virologic Failure (VF) Censored - VL < 50 HIV-1 RNA Subjects by Sex","description":"TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Count Using the Imputation Method of LOCF","description":"The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR). The Last Observation Carried Forward (LOCF) imputation method was applied.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":"12.7"},{"groupId":"OG001","value":"98","spread":"14.0"},{"groupId":"OG002","value":"113","spread":"12.1"},{"groupId":"OG003","value":"84","spread":"21.7"},{"groupId":"OG004","value":"90","spread":"22.6"},{"groupId":"OG005","value":"45","spread":"24.5"},{"groupId":"OG006","value":"138","spread":"41.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":287},"commonTop":["Nausea","Diarrhoea","Vomiting","Upper Respiratory Tract Infection","Cough"]}}}